MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0000
-0.0800 (-1.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0800
Open4.0000
Bid3.8500 x 1100
Ask4.8500 x 800
Day's Range3.8500 - 4.1000
52 Week Range2.3600 - 10.5400
Volume645,024
Avg. Volume530,936
Market Cap210.218M
Beta (3Y Monthly)4.31
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
    Simply Wall St.4 days ago

    Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

  • Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
    Zacks28 days ago

    Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

    Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

  • Associated Press2 months ago

    Marinus Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
    Simply Wall St.2 months ago

    How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?

    Every investor in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller...

  • Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
    Zacks3 months ago

    Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings

    Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.

  • Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
    Zacks3 months ago

    Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?

    Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.

  • Benzinga4 months ago

    Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why

    Shares of Marinus Pharmaceuticals Inc (NASDAQ: MRNS ), a micro-cap biotech focused on therapies for neuropsychiatric disorders, are likely to see upside amid some key near-term events, according to Jefferies.  ...

  • Main Line biopharm CEO stepping down
    American City Business Journals4 months ago

    Main Line biopharm CEO stepping down

    A Main Line biopharmaceutical company is searching for a new chief executive officer. Marinus Pharmaceuticals of Radnor said Tuesday its CEO, Christopher Cashman, is leaving the company effective March 18 to pursue other opportunities. In an interview with the Philadelphia Business Journal, Cashman said he would classify his departure as a "mutual" decision.

  • InvestorPlace5 months ago

    Zynerba Stock Is Marijuana-Adjacent Play Worth a Look

    Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.

  • Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
    Insider Monkey6 months ago

    Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]

  • Marinus Pharmaceuticals plans $45M stock sale
    American City Business Journals6 months ago

    Marinus Pharmaceuticals plans $45M stock sale

    Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.

  • Here's Why Marinus Pharmaceuticals Is Sinking Today
    Motley Fool6 months ago

    Here's Why Marinus Pharmaceuticals Is Sinking Today

    A secondary offering on the way isn't what investors wanted to hear.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...

  • Benzinga6 months ago

    Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials

    A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.

  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkey7 months ago

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
    Zacks8 months ago

    Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • Associated Press8 months ago

    Marinus Pharmaceuticals: 3Q Earnings Snapshot

    The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...

  • Simply Wall St.9 months ago

    What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?

    A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger10 months ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today
    Motley Fool11 months ago

    Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today

    The small biopharma announced second-quarter 2018 results and gave a business update.

  • Associated Press11 months ago

    Marinus Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. Marinus Pharmaceuticals shares have declined 14 percent since the beginning of the year. The stock has nearly ...

  • Benzinga11 months ago

    Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

    The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...